Technical Data Sheet
Survodutide
Also Known As: BI 456906, BI-456906, Survodutide peptide, GLP-1 glucagon dual agonist BI 456906, Boehringer dual agonist, GCGR GLP-1R dual agonist, GLP-1 glucagon obesity drug, Survodutide BI456906, Dual incretin glucagon agonist, GLP-1/glucagon dual agonist, survo, dual agonist
Scan To View Profile
| Evidence Tier | Investigational |
|---|---|
| Category | Weight Loss & Metabolism |
| Class | Synthetic dual agonist: GLP-1 receptor + glucagon receptor |
| Molecular Target | GLP-1R (satiety, insulin secretion) + GCGR (glucagon receptor: energy expenditure, hepatic lipid metabolism); dual incretin-glucagon signaling |
| Sequence | GLP-1/glucagon dual agonist (acylated synthetic peptide) |
| Molecular Weight | ~4232 g/mol |
| CAS | 2805997-46-8 |
| Parent | Oxyntomodulin-based |
| Mechanism | It is a dual agonist that hits both the GLP-1 receptor (to stop hunger) and the Glucagon receptor (to actively force the liver to burn stored fat and increase energy expenditure). |
| Studied For | Obesity / overweight, Type 2 diabetes, MASH / metabolic liver disease, Non-alcoholic steatohepatitis (NASH), Liver fat reduction, Dual GLP-1 glucagon therapy, HbA1c lowering, Body weight reduction, Cardiovascular risk reduction, Insulin resistance, Metabolic syndrome, Hepatic steatosis, Lipid metabolism, weight loss, liver fat reduction, NASH, NAFLD, obesity, energy expenditure increase |
| Administration Route | Injection Only |
| Form | lyophilized |
| Diluent | bacteriostatic or sterile water |
| Storage Temperature | frozen/refrigerated, dark |
| Light Sensitive | Yes |
| Freeze / Thaw | avoid |
| Reconstituted Shelf Life | 28 Days |
| Handling Notes | Note: catalog lists this as Survotutide (spelling). |
| Regulatory | Investigational (Boehringer Ingelheim / Zealand Pharma); not FDA-approved. Phase 3 SYNCHRONIZE-1 reported positive topline results on 28 April 2026, meeting co-primary endpoints with mean weight loss of up to 16.6% at 76 weeks versus 3.2% for placebo (efficacy estimand). Phase 3 SYNCHRONIZE-MASLD met both primary endpoints, with liver fat normalization in about 6 of 10 treated participants at 48 weeks. Full results were presented at the ADA 2026 Scientific Sessions and published in The New England Journal of Medicine and Nature Medicine. Holds FDA Breakthrough Therapy designation for MASH. Not on the WADA 2026 Prohibited List. |
| Sources |